公开(公告)号：US09341637B2

公开(公告)日：2016-05-17

申请号：US12943413

申请日：2010-11-10

申请人： Barry S. Coller ,  Dennis Durbin

发明人： Barry S. Coller ,  Dennis Durbin

IPC分类号： G01N33/86

CPC分类号： G01N33/86

摘要： A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi.

公开(公告)号：US20110065125A1

公开(公告)日：2011-03-17

申请号：US12876730

申请日：2010-09-07

申请人： Barry S. COLLER ,  Dennis Durbin

发明人： Barry S. COLLER ,  Dennis Durbin

IPC分类号： G01N33/53

CPC分类号： G01N33/86

摘要： A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi.

摘要翻译： 提供一种确定个体是否由于抑制血小板活化起始，信号转导和/或GPIIb / IIIa阻断而形成血小板血栓形成能力降低的方法。 从被评估的个体获得血液样本。 血液样品与1）抗凝剂混合; 2）足够的缓冲液将抗凝血液的pH和盐浓度保持在适合血小板聚集的范围内; 3）固定在固体表面上的血小板GPIIb / IIIa受体配体; 4）增强信号转导途径的一种或多种药物和5）受体激活剂。 将该组合在凝集颗粒的条件下孵育。 在搅拌的混合物中评估血小板介导的凝集。 没有凝集表明个体具有降低形成血小板血栓的能力。

公开(公告)号：US08574828B2

公开(公告)日：2013-11-05

申请号：US12876730

申请日：2010-09-07

申请人： Barry S Coller ,  Dennis Durbin

发明人： Barry S Coller ,  Dennis Durbin

IPC分类号： C12Q1/00

CPC分类号： G01N33/86

摘要： A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi.

摘要翻译： 提供一种确定个体是否由于抑制血小板活化起始，信号转导和/或GPIIb / IIIa阻断而形成血小板血栓形成能力降低的方法。 从被评估的个体获得血液样本。 血液样品与1）抗凝剂混合; 2）足够的缓冲液将抗凝血液的pH和盐浓度保持在适合血小板聚集的范围内; 3）固定在固体表面上的血小板GPIIb / IIIa受体配体; 4）增强信号转导途径的一种或多种药物和5）受体激活剂。 将该组合在凝集颗粒的条件下孵育。 在搅拌的混合物中评估血小板介导的凝集。 没有凝集表明个体具有降低形成血小板血栓的能力。

公开(公告)号：US20110081657A1

公开(公告)日：2011-04-07

申请号：US12943413

申请日：2010-11-10

申请人： Barry S. COLLER ,  Dennis Durbin

发明人： Barry S. COLLER ,  Dennis Durbin

IPC分类号： G01N33/53

CPC分类号： G01N33/86

摘要： A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi.

公开(公告)号：US07790362B2

公开(公告)日：2010-09-07

申请号：US10886155

申请日：2004-07-06

申请人： Barry S. Coller ,  Dennis Durbin

发明人： Barry S. Coller ,  Dennis Durbin

IPC分类号： C12Q1/00

CPC分类号： G01N33/86

摘要： A method is provided of determining whether an individual has reduced ability to form platelet thrombi. An ADP platelet activator and one or platelet inhibitors are provided. At least one of the platelet inhibitors is Prostaglandin E1 (PGE1). An alternate signal transduction pathway is produced. A final concentration of ADP is 2 to 35 μM and a final concentration of PGE1 is 2 to 30 nM, preferably 20 to 25 nM.

摘要翻译： 提供一种确定个体是否具有降低形成血小板血栓形成能力的方法。 提供ADP血小板激活剂和一种或血小板抑制剂。 至少有一种血小板抑制剂是前列腺素E1（PGE1）。 产生替代的信号转导途径。 ADP的终浓度为2〜35μM，PGE1的终浓度为2〜30nM，优选为20〜25nM。

公开(公告)号：US09506938B2

公开(公告)日：2016-11-29

申请号：US12598581

申请日：2008-05-01

申请人： Barry Coller ,  Dennis Durbin

发明人： Barry Coller ,  Dennis Durbin

IPC分类号： G01N33/86

CPC分类号： G01N33/86 ,  G01N2800/222 ,  G01N2800/226 ,  G01N2800/50

摘要： A method is provided for measuring inhibition of platelet reactivity in an individual treated with a drug-eluting stent (DES). First, a blood sample is obtained from an individual treated with a DES and a P2Y12 antagonist. The blood sample is then mixed with particles comprising an attached GPIIb/IIIa receptor ligand, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1). The mixture is incubated under conditions suitable for agglutinating particles, and platelet-mediated agglutination is assessed in the mixture. The absence or reduction of agglutination indicates that the individual treated with a DES has reduced platelet reactivity. Also provided is a kit for measuring inhibition of platelet aggregation by a P2Y12 receptor antagonist that includes a GPIIb/IIIa receptor ligand immobilized on a particle, adenosine diphosphate (ADP), prostaglandin E1 (PGE1), an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation.

摘要翻译： 提供了用于测量用药物洗脱支架（DES）处理的个体中血小板反应性抑制的方法。 首先，从用DES和P2Y12拮抗剂处理的个体获得血液样品。 然后将血液样品与包含附着的GPIIb / IIIa受体配体，二磷酸腺苷（ADP）和前列腺素E1（PGE1）的颗粒混合。 将混合物在适合于凝集颗粒的条件下孵育，并在混合物中评估血小板介导的凝集。 凝集的不存在或减少表明用DES处理的个体降低了血小板反应性。 还提供了一种用于测量P2Y12受体拮抗剂抑制血小板聚集的试剂盒，其包括固定在颗粒上的GPIIb / IIIa受体配体，二磷酸腺苷（ADP），前列腺素E1（PGE1），抗凝血剂和缓冲液，以维持 抗凝血液适合血小板聚集。

公开(公告)号：US07494338B2

公开(公告)日：2009-02-24

申请号：US11032851

申请日：2005-01-11

申请人： Duane Durbin ,  Dennis Durbin ,  Arun Dalmia ,  Ed Childers

发明人： Duane Durbin ,  Dennis Durbin ,  Arun Dalmia ,  Ed Childers

IPC分类号： A61C1/00 ,  A61C19/04

CPC分类号： A61C9/00 ,  A61C9/0053 ,  G06T17/00

摘要： Systems and methods for optically imaging a dental structure within an oral cavity by moving one or more image apertures on an arm coupled to a fixed coordinate reference frame external to the oral cavity; determining the position of the one or more image apertures using the fixed external coordinate reference frame; capturing one or more images of the dental structure through one or more of the image apertures; and generating a 3D model of the dental structure based on the captured images.

摘要翻译： 通过移动耦合到口腔外部的固定坐标参考系的臂上的一个或多个图像孔来光学地成像口腔内牙科结构的系统和方法; 使用固定的外部坐标参考系确定所述一个或多个图像孔径的位置; 通过一个或多个图像孔捕获牙科结构的一个或多个图像; 以及基于所捕获的图像生成所述牙科结构的3D模型。

公开(公告)号：US20070007353A1

公开(公告)日：2007-01-11

申请号：US11352441

申请日：2006-02-08

申请人： Arvin Danielson ,  Dennis Durbin ,  George Hanson

发明人： Arvin Danielson ,  Dennis Durbin ,  George Hanson

IPC分类号： G06K7/10

CPC分类号： G06K7/10881

摘要： A portable, hand-held data processing assembly of modular structure includes a base unit with a keyboard and a display screen. An indicia reader module is housed in a housing shell which is attachable to the base unit. The indicia reader module can contain a reflected light indicia reader for non-contact essentially instantaneous reading of bar codes of the like disposed in a spaced, non-contacting relationship to the assembly. The indicia reader module can also include a processor. The base can include a light source. Additionally, the base unit can include a battery for powering the hand-held data processing assembly. A data collection and communications module can include a stacked arrangement of a communications interface main circuit board, a radio and a laser scanner assembly which are housed in a housing shell attachable to the base unit. In this arrangement, the radio is mounted in spaced relationship to one side of the main circuit board, while the laser scanner assembly is mounted to the other side of the main circuit board. A support frame and a plurality of ground planes in the sandwiched main circuit board and a routing circuit board form an RF cage for shielding RF interference which may be generated by the radio. Also disclosed is a method for reducing the operational power consumption requirements of laser bar code scanners by analyzing reflected laser light in order to determine the presence of optically readable information sets.

摘要翻译： 一种模块化结构的便携式手持式数据处理组件包括具有键盘和显示屏的基座单元。 标记读取器模块容纳在可附接到基座单元的壳体壳体中。 标记读取器模块可以包含反射光标记读取器，用于非接触式基本上瞬时读取与组件间隔开的非接触关系的条形码。 标记读取器模块还可以包括处理器。 基座可以包括光源。 此外，基本单元可以包括用于为手持数据处理组件供电的电池。 数据收集和通信模块可以包括通信接口主电路板，无线电和激光扫描器组件的堆叠布置，其被收纳在可附接到基座单元的壳体壳体中。 在这种布置中，无线电装置以与主电路板的一侧隔开的关系安装，而激光扫描器组件安装到主电路板的另一侧。 在夹层主电路板和布线电路板中的支撑框架和多个接地平面形成用于屏蔽由无线电产生的RF干扰的RF笼。 还公开了一种通过分析反射的激光来降低激光条形码扫描器的操作功耗要求的方法，以便确定光学可读信息集的存在。

公开(公告)号：US20100184084A1

公开(公告)日：2010-07-22

申请号：US12598581

申请日：2008-05-01

申请人： Barry Coller ,  Dennis Durbin

发明人： Barry Coller ,  Dennis Durbin

IPC分类号： G01N33/53

CPC分类号： G01N33/86 ,  G01N2800/222 ,  G01N2800/226 ,  G01N2800/50

摘要： A method is provided for measuring inhibition of platelet reactivity in an individual treated with a drug-eluting stent (DES). First, a blood sample is obtained from an individual treated with a DES and a P2Y12 antagonist. The blood sample is then mixed with particles comprising an attached GPIIb/IIIa receptor ligand, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1). The mixture is incubated under conditions suitable for agglutinating particles, and platelet-mediated agglutination is assessed in the mixture. The absence or reduction of agglutination indicates that the individual treated with a DES has reduced platelet reactivity. Also provided is a kit for measuring inhibition of platelet aggregation by a P2Y12 receptor antagonist that includes a GPIIb/IIIa receptor ligand immobilized on a particle, adenosine diphosphate (ADP), prostaglandin E1 (PGE1), an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation.

摘要翻译： 提供了用于测量用药物洗脱支架（DES）处理的个体中血小板反应性抑制的方法。 首先，从用DES和P2Y12拮抗剂处理的个体获得血液样品。 然后将血液样品与包含附着的GPIIb / IIIa受体配体，二磷酸腺苷（ADP）和前列腺素E1（PGE1）的颗粒混合。 将混合物在适合于凝集颗粒的条件下孵育，并在混合物中评估血小板介导的凝集。 凝集的不存在或减少表明用DES处理的个体降低了血小板反应性。 还提供了用于测量P2Y12受体拮抗剂抑制血小板聚集的试剂盒，其包括固定在颗粒上的GPIIb / IIIa受体配体，二磷酸腺苷（ADP），前列腺素E1（PGE1），抗凝血剂和缓冲液，以维持 抗凝血液适合血小板聚集。

公开(公告)号：US20060246528A1

公开(公告)日：2006-11-02

申请号：US11411239

申请日：2006-04-24

申请人： Lisa Swaim ,  Dennis Durbin

发明人： Lisa Swaim ,  Dennis Durbin

IPC分类号： C12Q1/56 ,  G06F19/00

CPC分类号： C12Q1/56 ,  G01N33/86

摘要： A method for obtaining a percent aggregation or inhibition of platelets resulting from anti-platelet using a single blood sample is achieved. An assay device is provided. The assay device has multiple channels, each coupled to a common introduction port. A first platelet activator is sensitive to activation pathway targeted by the anti-platelet drug. A second platelet activator is insensitive to the activation pathway targeted by the anti-platelet drug. An anti-coagulated sample is introduced simultaneously to the first and second channels. A level of platelet aggregation is simultaneously made in both channels

摘要翻译： 实现了使用单一血液样品获得由抗血小板产生的血小板聚集或抑制百分比的方法。 提供测定装置。 测定装置具有多个通道，每个通道耦合到公共引入端口。 第一种血小板活化剂对抗血小板药物靶向的活化途径敏感。 第二种血小板激活剂对抗血小板药物靶向的激活途径不敏感。 将抗凝凝样品同时引入第一和第二通道。 在两个通道中同时进行血小板聚集的水平